What version are you using? "NCCN Guidelines for Prostate Cancer"
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Reviewed by Dr. Chris Apfel, MD/PhD (UCSF)
About the NCCN Guidelines I'm Referencing
That's an excellent question—transparency matters when you're making healthcare decisions.
Based on the medical context I have available, I'm referencing the 2024 NCCN Guidelines for Prostate Cancer, specifically:
- NCCN Guidelines for Patients: Early-Stage Prostate Cancer (2024)
- NCCN Guidelines for Patients: Advanced-Stage Prostate Cancer (2024)
These are the patient-friendly versions of the NCCN guidelines, which translate the clinical recommendations into understandable language.
Important Note About Guideline Versions
NCCN updates its guidelines regularly (typically annually or more frequently as new evidence emerges). To ensure you have the most current recommendations for your specific situation, I recommend:
- Visit NCCN directly: www.nccn.org/patients
- Ask your oncology team: "Are you using the current NCCN guidelines, and have there been any recent updates relevant to my treatment?"
- Check the publication date: Guidelines evolve as new treatments and research become available
Why This Matters for You
With stage 4 prostate cancer, treatment options and recommendations can change as:
- New drugs receive FDA approval
- Clinical trial data emerges
- Biomarker testing becomes more refined
Your oncologist should be using the most current guidelines available and can tell you exactly which version they're following.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ